NZ753459A - 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer - Google Patents
6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancerInfo
- Publication number
- NZ753459A NZ753459A NZ753459A NZ75345917A NZ753459A NZ 753459 A NZ753459 A NZ 753459A NZ 753459 A NZ753459 A NZ 753459A NZ 75345917 A NZ75345917 A NZ 75345917A NZ 753459 A NZ753459 A NZ 753459A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- pyrazolo
- tetrahydro
- cancer
- derivatives useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411799P | 2016-10-24 | 2016-10-24 | |
| US201662435159P | 2016-12-16 | 2016-12-16 | |
| PCT/EP2017/076191 WO2018077630A1 (en) | 2016-10-24 | 2017-10-13 | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ753459A true NZ753459A (en) | 2023-01-27 |
Family
ID=60083331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ753459A NZ753459A (en) | 2016-10-24 | 2017-10-13 | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
Country Status (37)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3355884T1 (sl) | 2015-10-01 | 2021-11-30 | Olema Pharmaceuticals, Inc. | Antiestrogenska zdravila tetrahidro-1H-pirido(3,4-b)indola |
| JP7241542B2 (ja) * | 2016-04-08 | 2023-03-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用 |
| US10125135B2 (en) | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
| TW201815789A (zh) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | 化合物 |
| JOP20190090B1 (ar) | 2016-10-24 | 2023-03-28 | Astrazeneca Ab | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان |
| RS63500B1 (sr) | 2016-12-16 | 2022-09-30 | Janssen Pharmaceutica Nv | Jedinjenja imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaza |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| CR20190379A (es) | 2017-01-30 | 2019-10-21 | Astrazeneca Ab | Moduladores del receptor de estrógeno |
| WO2019002441A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| WO2019002442A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| US11236088B2 (en) | 2017-11-14 | 2022-02-01 | Kind Pharmaceutical | Heterocyclic compounds and their application in medicine |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| US11993574B2 (en) | 2018-06-15 | 2024-05-28 | Reata Pharmaceuticals, Inc | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| MX2021001857A (es) | 2018-08-17 | 2021-10-13 | Genentech Inc Star | Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama. |
| CN109053524A (zh) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种N-Boc-3-羟基氮杂环丁烷的制备方法 |
| CN114302722A (zh) | 2019-07-07 | 2022-04-08 | 奥列马制药公司 | 雌激素受体拮抗剂方案 |
| US20230068370A1 (en) * | 2019-12-20 | 2023-03-02 | Recurium Ip Holdings, Llc | Combinations |
| TWI882060B (zh) | 2020-01-10 | 2025-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 三環四氫異喹啉類衍生物、其製備方法及其在醫藥上的應用 |
| PH12022552755A1 (en) * | 2020-04-24 | 2024-03-25 | Astrazeneca Ab | Pharmaceutical formulations |
| MX2022013391A (es) * | 2020-04-24 | 2022-11-30 | Astrazeneca Ab | Pauta posologica para el tratamiento del cancer. |
| JP7720906B2 (ja) * | 2020-05-15 | 2025-08-08 | シムサー ファーマシューティカル カンパニー リミテッド | ピロリジン化合物及びその使用 |
| CN115697987B (zh) * | 2020-06-12 | 2025-08-05 | 海南先声再明医药股份有限公司 | 雌激素受体调节剂化合物及其用途 |
| CN115916769B (zh) * | 2020-06-28 | 2024-09-10 | 深圳扬厉医药技术有限公司 | 并环吲唑类化合物 |
| CN114105977B (zh) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | 雌激素受体调节剂化合物及其用途 |
| KR20220107752A (ko) | 2021-01-26 | 2022-08-02 | 충북대학교 산학협력단 | 피라졸로퀴놀린 유도체 및 이의 항암제로서의 용도 |
| WO2022166980A1 (zh) * | 2021-02-08 | 2022-08-11 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| AU2022233254A1 (en) | 2021-03-11 | 2023-10-26 | Janssen Pharmaceutica Nv | Lorpucitinib for use in the treatment of jak mediated disorders |
| US12410155B2 (en) | 2021-12-28 | 2025-09-09 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Salt form and crystal form of tetrahydrocyclohepta indazole compound |
| AU2023362285A1 (en) | 2022-10-17 | 2025-05-29 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
| WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
| US20240180893A1 (en) | 2022-11-17 | 2024-06-06 | Astrazeneca Ab | Methods of treatment of breast cancer |
| TW202508573A (zh) | 2023-05-11 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| WO2025175249A1 (en) * | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| AU2001287654B2 (en) | 2000-08-10 | 2006-12-14 | Pfizer Italia S.R.I. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| JP2008534496A (ja) | 2005-03-22 | 2008-08-28 | アストラゼネカ・アクチエボラーグ | ＣＢ１’受容体リガンドとしての新規なテトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール誘導体 |
| FR2884252B1 (fr) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
| AR058223A1 (es) | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| MX373926B (es) | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| US20120157401A1 (en) | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| WO2010138659A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| CN102939287B (zh) | 2010-06-10 | 2016-01-27 | 塞拉根制药公司 | 雌激素受体调节剂及其用途 |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| ES2586908T3 (es) * | 2010-12-24 | 2016-10-19 | Merck Sharp & Dohme B.V. | Derivados de azetidina N-sustituidos |
| US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| UY35590A (es) | 2013-05-28 | 2014-11-28 | Astrazeneca Ab | Nuevos compuestos para el tratamiento del cáncer |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| PE20160157A1 (es) | 2013-06-19 | 2016-03-18 | Seragon Pharmaceuticals Inc | Moduladores de los receptores de estrogeno y sus usos |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| KR20250044940A (ko) | 2014-12-18 | 2025-04-01 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
| EP3233818A1 (en) | 2014-12-18 | 2017-10-25 | F. Hoffmann-La Roche AG | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
| US9845291B2 (en) * | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| JP6768711B2 (ja) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
| US10087191B2 (en) * | 2015-06-16 | 2018-10-02 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
| CN106518768B (zh) | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的应用 |
| SI3355884T1 (sl) | 2015-10-01 | 2021-11-30 | Olema Pharmaceuticals, Inc. | Antiestrogenska zdravila tetrahidro-1H-pirido(3,4-b)indola |
| HK1258851A1 (zh) | 2015-11-09 | 2019-11-22 | 豪夫迈‧罗氏有限公司 | 四氢萘雌激素受体调节剂及其用途 |
| CA3011391C (en) | 2015-11-12 | 2021-02-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| KR20180095564A (ko) | 2015-12-22 | 2018-08-27 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 벤조피페리딘 유도체, 이의 제조 방법 및 이의 의학적 용도 |
| JP7241542B2 (ja) * | 2016-04-08 | 2023-03-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用 |
| WO2017182495A1 (en) * | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity |
| US10125135B2 (en) * | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
| WO2017192991A1 (en) | 2016-05-06 | 2017-11-09 | Xavier University Of Louisiana | Selective estrogen receptor down-regulators (serds) |
| WO2018001232A1 (zh) | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| TW201815789A (zh) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | 化合物 |
| CN107814798B (zh) | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| CA3087528C (en) | 2016-09-15 | 2024-01-30 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| JOP20190090B1 (ar) * | 2016-10-24 | 2023-03-28 | Astrazeneca Ab | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان |
| BR102016024814A2 (pt) | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| WO2018108671A1 (en) | 2016-12-16 | 2018-06-21 | Basf Se | Pesticidal compounds |
| RS63500B1 (sr) | 2016-12-16 | 2022-09-30 | Janssen Pharmaceutica Nv | Jedinjenja imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaza |
| GEAP202115110A (en) | 2016-12-16 | 2021-02-25 | Pfizer Inc | Glp-1 receptor agonists and uses thereof |
| EP3555105B1 (en) | 2016-12-16 | 2020-10-28 | Eli Lilly and Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| ES2866152T3 (es) | 2017-01-30 | 2021-10-19 | Chiesi Farm Spa | Derivados de tirosina amida como inhibidores de la Rho-quinasa |
-
2017
- 2017-10-13 JO JOP/2019/0090A patent/JOP20190090B1/ar active
- 2017-10-13 PT PT191890102T patent/PT3640251T/pt unknown
- 2017-10-13 NZ NZ753459A patent/NZ753459A/en unknown
- 2017-10-13 CA CA3040040A patent/CA3040040A1/en active Pending
- 2017-10-13 JP JP2019520525A patent/JP6744489B2/ja active Active
- 2017-10-13 PE PE2019000845A patent/PE20191078A1/es unknown
- 2017-10-13 SI SI201730111T patent/SI3433256T1/sl unknown
- 2017-10-13 PL PL17783857T patent/PL3433256T3/pl unknown
- 2017-10-13 PT PT177838570T patent/PT3433256T/pt unknown
- 2017-10-13 PL PL19189010T patent/PL3640251T3/pl unknown
- 2017-10-13 HR HRP20220255TT patent/HRP20220255T1/hr unknown
- 2017-10-13 RS RSP20191371 patent/RS59445B1/sr unknown
- 2017-10-13 ME MEP-2019-306A patent/ME03547B/me unknown
- 2017-10-13 LT LT17783857T patent/LT3433256T/lt unknown
- 2017-10-13 TW TW106135012A patent/TWI735681B/zh active
- 2017-10-13 US US15/782,904 patent/US10131663B2/en active Active
- 2017-10-13 ES ES19189010T patent/ES2907759T3/es active Active
- 2017-10-13 AU AU2017349797A patent/AU2017349797B2/en active Active
- 2017-10-13 HU HUE17783857A patent/HUE045714T2/hu unknown
- 2017-10-13 CN CN201780064567.7A patent/CN109843888B/zh active Active
- 2017-10-13 CR CR20190204A patent/CR20190204A/es unknown
- 2017-10-13 EP EP17783857.0A patent/EP3433256B1/en active Active
- 2017-10-13 UA UAA201905126A patent/UA125824C2/uk unknown
- 2017-10-13 SI SI201731087T patent/SI3640251T1/sl unknown
- 2017-10-13 SM SM20190602T patent/SMT201900602T1/it unknown
- 2017-10-13 HU HUE19189010A patent/HUE057524T2/hu unknown
- 2017-10-13 SM SM20220098T patent/SMT202200098T1/it unknown
- 2017-10-13 DK DK17783857T patent/DK3433256T3/da active
- 2017-10-13 WO PCT/EP2017/076191 patent/WO2018077630A1/en not_active Ceased
- 2017-10-13 MX MX2019004685A patent/MX382331B/es unknown
- 2017-10-13 SG SG11201903182XA patent/SG11201903182XA/en unknown
- 2017-10-13 MY MYPI2019002161A patent/MY205300A/en unknown
- 2017-10-13 LT LTEP19189010.2T patent/LT3640251T/lt unknown
- 2017-10-13 DK DK19189010.2T patent/DK3640251T3/da active
- 2017-10-13 KR KR1020197014062A patent/KR102178692B1/ko active Active
- 2017-10-13 EP EP19189010.2A patent/EP3640251B1/en active Active
- 2017-10-13 CN CN202210381693.8A patent/CN114656464B/zh active Active
- 2017-10-13 ES ES17783857T patent/ES2751902T3/es active Active
-
2018
- 2018-10-09 US US16/155,041 patent/US10590130B2/en active Active
-
2019
- 2019-02-01 ZA ZA2019/00694A patent/ZA201900694B/en unknown
- 2019-04-16 PH PH12019500830A patent/PH12019500830A1/en unknown
- 2019-04-18 CL CL2019001077A patent/CL2019001077A1/es unknown
- 2019-04-18 CO CONC2019/0003950A patent/CO2019003950A2/es unknown
- 2019-04-22 IL IL266245A patent/IL266245B/en active IP Right Grant
- 2019-04-23 EC ECSENADI201928657A patent/ECSP19028657A/es unknown
- 2019-04-23 DO DO2019000104A patent/DOP2019000104A/es unknown
- 2019-04-24 NI NI201900039A patent/NI201900039A/es unknown
- 2019-10-24 CY CY20191101110T patent/CY1122566T1/el unknown
-
2020
- 2020-01-28 US US16/774,268 patent/US10961241B2/en active Active
- 2020-07-30 JP JP2020129457A patent/JP6993477B2/ja active Active
-
2021
- 2021-02-17 US US17/177,617 patent/US12077530B2/en active Active
-
2022
- 2022-02-23 CY CY20221100160T patent/CY1125292T1/el unknown
-
2024
- 2024-07-17 US US18/775,391 patent/US20240383895A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| PH12021552083A1 (en) | Fused tricyclic compounds useful as anticancer agents | |
| TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
| PH12017500367A1 (en) | Compounds that inhibit mcl-1 protein | |
| PH12017502246B1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| PH12015502615B1 (en) | Chemical compounds | |
| MX2021001096A (es) | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. | |
| ZA202400595B (en) | Spirocyclic compounds | |
| PH12019501724A1 (en) | Estrogen receptor modulators | |
| TW201613864A (en) | Novel compounds | |
| PH12015500063B1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| WO2014160143A3 (en) | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | |
| MY166057A (en) | Carbocyclic nucleosides and their pharmaceutical use and compositions | |
| EA201990943A1 (ru) | 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2024 BY CPA GLOBAL Effective date: 20230831 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240829 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2026 BY ANAQUA SERVICES Effective date: 20250924 |